NCT06293898 - Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Biotech Hunter

Enrollment

280

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

August 24, 2025

Study Completion Date

August 24, 2027

Conditions

Endometrial CancerCervical CancerOvarian CancerUrothelial CarcinomaBiliary Tract CancerBreast CancerLung CancerGastric CancerGastroesophageal-junction CancerEsophageal Cancer

Interventions

DRUG

BL-M07D1

"Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 by intravenous infusion every 3 weeks.~Other Names:~BL-M07D1"

Trial Locations (10)

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

30912

RECRUITING

Georgia Cancer Center at Augusta University, Augusta

32827

RECRUITING

Sarah Cannon Research institute - Lake Nona Florida, Orlando

33146

RECRUITING

University of Miami, Miami

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

48201

RECRUITING

Karmanos Cancer Institiute, Detroit

60612

RECRUITING

University of Illinois Cancer Center, Chicago

77030

RECRUITING

Oncology Consultants, Houston

91010

RECRUITING

City of Hope, Duarte

02215

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors

lead

SystImmune Inc.

INDUSTRY